摘要
目的 探讨单用重组人促红细胞生成素(rHuEPO)疗效不佳慢性肾衰竭(CRF)维持性血液透析(MHD)肾性贫血(RA)患者应用低剂量罗沙司他联合rHuEPO治疗的效果。方法 选取100例单用rHuEPO疗效不佳CRF MHD RA患者,随机分为对照组(n=50)和观察组(n=50)。对照组使用r HuEPO+多糖铁治疗,观察组在对照组基础上联合使用低剂量罗沙司他胶囊治疗。比较两组患者的治疗效果、贫血恢复指标、微炎症指标、不良反应发生情况。结果 与对照组的84.00%比较,观察组总有效率98.00%更高,差异有统计学意义(P<0.05)。治疗后,观察组血红蛋白(131.26±9.77)g/L、红细胞比容(48.50±5.28)%、促红细胞生成素(EPO)(22.39±3.48)U/L、铁蛋白(587.85±28.36)μg/L、转铁蛋白(2.83±0.74)g/L高于对照组的(113.42±8.65)g/L、(36.46±5.07)%、(15.18±3.11)U/L、(425.31±26.64)μg/L、(1.96±0.41)g/L,C反应蛋白(10.34±2.18)mg/L、β2微球蛋白(10.69±2.74)mg/L低于对照组的(13.87±2.67)、(14.87±3.12)mg/L,差异有统计学意义(P<0.05)。两组治疗后血沉比较差异无统计学意义(P>0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论 低剂量罗沙司他联合r HuEPO治疗单用rHuEPO疗效不佳CRF MHD RA患者疗效好,可有效改善患者贫血症状,降低血清微炎症指标,且安全性较高。
Objective To explore the effect of low-dose roxadustat combined with recombinant human erythropoietin(rHuEPO) in the treatment of patients with renal anemia(RA) and maintenance hemodialysis(MHD) for chronic renal failure(CRF) with poor efficacy of rHuEPO alone.Methods A total of 100 cases of CRF MHD RA patients with poor efficacy of rHuEPO alone were randomly divided into a control group(n=50) and an observation group(n=50).The control group was treated with rHuEPO+ polysaccharide iron complex,and the observation group was treated with low-dose roxadustat capsules on the basis of the control group.The therapeutic effect,anemia recovery indicators,microinflammatory indicators and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 98.00%,which was higher than 84.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,the hemoglobin of the observation group was(131.26±9.77) g/L,the hematocrit was(48.50±5.28) %,the erythropoietin(EPO) was(22.39±3.48) U/L,the ferritin was(587.85±28.36) μg/L and the transferrin was(2.83±0.74) g/L,which were higher than(113.42±8.65) g/L,(36.46±5.07) %,(15.18±3.11) U/L,(425.31±26.64) μg/L and(1.96±0.41) g/L of the control group;the C-reactive protein and β2 microglobulin of the observation group were(10.34±2.18) mg/L(10.69±2.74) mg/L,which were lower than(13.87±2.67) and(14.87±3.12) mg/L of the control group;the difference was statistically significant(P<0.05).There was no significant difference in erythrocyte sedimentation rate between the two groups after treatment(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Low-dose roxadustat combined with rHuEPO is effective in treating patients with CRF MHD RA who have poor efficacy of rHuEPO alone,which can effectively improve patients' anemia symptoms and reduce serum microinflammatory indicators,and has a high safety profile.
作者
袁雪雁
陈嘉琦
叶庆邦
卓华钦
YUAN Xue-yan;CHEN Jia-qi;YE Qing-bang(Songshan Lake Central Hospital,Dongguan 523000,China)
出处
《中国现代药物应用》
2024年第22期16-19,共4页
Chinese Journal of Modern Drug Application
